Mepolizumab for severe asthma flare-ups after treatment
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial studies whether mepolizumab can reduce ongoing or returning asthma flare-ups in people with severe asthma. If you have severe asthma that still keeps flaring, this may help by targeting a specific inflammation pathway involved in some asthma cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a proven diagnosis of severe asthma (as defined by the Canadian Thoracic Society).
- Your doctor says you’re eligible to receive mepolizumab.
- You can and are willing to sign the informed consent form.
- You do not have any lung or breathing disease other than asthma.
- You do not have certain related conditions (like EGPA or hypereosinophilic syndrome).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and other measures (biomarkers) to understand how well mepolizumab helps people with nasal polyps, with or without asthma. It aims to find response clues that could help personalize treatment in the future.
This trial tests reslizumab, a medicine that targets a specific immune signal, to improve symptoms in people with eosinophilic granulomatosis with polyangiitis (EGPA). It may help lower disease activity and reduce inflammation-related problems.
This trial tests a new medicine, QL2302, to see how well it works compared to an approved treatment called Tezspire for people with severe asthma. If you have asthma that is not well controlled despite using daily inhalers and other medications, you may be able to join.
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
This study looks at why some people with severe chronic nasal polyps respond better to mepolizumab. It may help doctors predict who will benefit from the medicine, and who may need a different plan.
This study tests if the drug mepolizumab can reduce mucus blockages in the airways of people with COPD and frequent flare-ups. It may help improve breathing and reduce flare-ups.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.